Navigation
-
Daniel J. O’Connor, President and Chief Executive Officer of Advaxis, Appointed to Board of Trustees of BioNJ
-
Advaxis’ Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal
-
Advaxis Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor
-
Advaxis Expands Intellectual Property for Lm Technology™ Platform
-
Advaxis Provides 2016 Business Outlook
-
Advaxis Establishes Scientific Advisory Board With Several Distinguished Experts
-
FDA Lifts Advaxis Clinical Hold
-
Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer
-
Advaxis to Present Poster on ADXS-HER2 at SABCS 2015
-
Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
